Dear Dr. Raineri:

Please refer to your new drug application (NDA) dated November 28, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Inspra (eplerenone) 25, 50, & 100 mg Tablets.

We acknowledge receipt of your submissions dated January 3, 4, 11, 14, 15, 16 and 22; April 5 and 30; May 9, 16 and 17; July 12; August 21, 22 (three), 26 and 29; and September 9 and 18, 2002.

This new drug application provides for the use of Inspra (eplerenone) 25, 50, & 100 mg Tablets for the treatment of hypertension, alone or in combination with other agents.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed text for the package insert, and the immediate container and carton labels included in your August 29, 2002 submission revised according to our September 12, 2002 e-mail. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-437." Approval of this submission by FDA is not required before the labeling is used.

We note our written request for pediatric studies for eplerenone dated August 17, 2000. We are deferring submission of your pediatric studies until August 17, 2004.

In addition, please submit three copies of the introductory promotional materials that you propose to
use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Cardio-Renal Drug Products and two copies of both promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

In addition, we recommend the following:
• A retest date of (b)-----------------for the drug substance
• An expiration-dating period of(b)-----------------for the drug product will be granted based on stability data provided

The following dissolution method and specification are recommended:
• USP Apparatus II at 50 RPM in 1000 ml of 0.1 N HCl  
• Specification not less than (b)--in 30 minutes

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Mr. Daryl Allis  
Regulatory Health Project Manager  
(301) 594-5309

Sincerely,

[See appended electronic signature page]

Robert Temple, M.D.  
Director  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Robert Temple
10/7/02 11:06:04 AM